Atara Biotherapeutics Inc (NASDAQ: ATRA) kicked off on Tuesday, up 9.26% from the previous trading day, before settling in for the closing price of $12.20. Over the past 52 weeks, ATRA has traded in a range of $6.50-$39.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 25.21% over the last five years. While this was happening, its average annual earnings per share was recorded 90.56%. With a float of $4.23 million, this company’s outstanding shares have now reached $5.74 million.
The firm has a total of 225 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.7%, operating margin of -119.24%, and the pretax margin is -132.56%.
Atara Biotherapeutics Inc (ATRA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Atara Biotherapeutics Inc is 26.50%, while institutional ownership is 42.26%. The most recent insider transaction that took place on Nov 18 ’24, was worth 11,198. In this transaction EVP, Chief Regulatory Officer of this company sold 1,000 shares at a rate of $11.20, taking the stock ownership to the 19,378 shares. Before that another transaction happened on Nov 18 ’24, when Company’s EVP, CFO and COO sold 1,364 for $11.20, making the entire transaction worth $15,274. This insider now owns 23,392 shares in total.
Atara Biotherapeutics Inc (ATRA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.56% per share during the next fiscal year.
Atara Biotherapeutics Inc (NASDAQ: ATRA) Trading Performance Indicators
Take a look at Atara Biotherapeutics Inc’s (ATRA) current performance indicators. Last quarter, stock had a quick ratio of 0.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -25.66, a number that is poised to hit -1.85 in the next quarter and is forecasted to reach -2.62 in one year’s time.
Technical Analysis of Atara Biotherapeutics Inc (ATRA)
Analysing the last 5-days average volume posted by the [Atara Biotherapeutics Inc, ATRA], we can find that recorded value of 0.11 million was better than the volume posted last year of 0.1 million. As of the previous 9 days, the stock’s Stochastic %D was 84.08%. Additionally, its Average True Range was 1.04.
During the past 100 days, Atara Biotherapeutics Inc’s (ATRA) raw stochastic average was set at 81.02%, which indicates a significant decrease from 93.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.82% in the past 14 days, which was lower than the 107.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.90, while its 200-day Moving Average is $11.68. Now, the first resistance to watch is $13.76. This is followed by the second major resistance level at $14.19. The third major resistance level sits at $14.99. If the price goes on to break the first support level at $12.53, it is likely to go to the next support level at $11.73. Should the price break the second support level, the third support level stands at $11.30.
Atara Biotherapeutics Inc (NASDAQ: ATRA) Key Stats
The company with the Market Capitalisation of 76.78 million has total of 5,760K Shares Outstanding. Its annual sales at the moment are 8,570 K in contrast with the sum of -276,130 K annual income. Company’s last quarter sales were recorded 40,190 K and last quarter income was -21,910 K.
